



PEPTIDE THERAPEUTICS FOUNDATION

Promoting research and development of peptide therapeutics

PEPTIDE THERAPEUTICS DATABASE 2010



TABLE OF CONTENTS

Data collection and sources	2
Sponsorship	2
Field Definitions	3
All Therapeutic Peptides	7
Approved Peptides	57
Discontinued Peptides	73
Peptides in Phase 1 Development	91
Peptides in Phase 2 Development	99
Peptides in Phase 3 Development and Preregistration	113

DATA COLLECTION AND SOURCES


The Therapeutic Peptide Database was generated in October of 2009 based on public information released by pharmaceutical and biotechnology firms involved in the development of peptide therapeutics. Classification as a peptide required that each new chemical entity (NCE) was composed of a minimum of two amino acids coupled together through an amide bond. No maximum number of amino acids was defined for synthetic peptides however a maximum length of 50 amino acids was imposed for recombinant peptide candidates. Peptides produced via fermentation (e.g., certain peptide antibiotics) were also excluded from the data set.

Currently the data set includes 334 entries documenting information such as: INN and/or compound name; indications studied; current development status; size of peptide; topology; manufacturing method and molecular target. Data were collected from public sources including but not limited to: company web sites, press releases, annual reports, meeting reports, investor presentations, clinicaltrials.gov, biomedical literature, Drugs@fda and emea.europa.eu. Where necessary the information was cross-referenced with public information available in a variety of commercial databases (e.g., IDdb3, Adis Insight, IMS R&D Focus, PharmaProjects, NDA Pipeline). A final manual curation was performed to address any inconsistency between the different data sources. To the best of our knowledge, at the time of printing the information contained in this report is complete and accurate.

The Peptide Therapeutics Foundation welcomes and will incorporate into the next edition any corrections that we receive.

SPONSORSHIP

Generation and production of the peptide data set is underwritten by an unrestricted guaranteed grant from Amylin Pharmaceuticals, Ferring Research Institute, Ipsen



ALL PEPTIDES : ALPHABETICAL LISTING

INN and/ or Compound Name	Brand Name	Company	All indications	Approved Indications	Highest Development Status	Current Development Status	Date first entered clinic	Phase 2 Start Date	Phase 3 Start Date	First Approval Date	First Approval Region
A-6		Angstrom Pharmaceuticals Inc	Ovarian cancer Age-related macular degeneration Diabetic retinopathy		Phase 2	Phase 2	7/2/2003	6/3/2004			
A-623 AMG-623		Anthera Pharmaceuticals	Lupus erythematosus Chronic lymphocytic leukemia		Phase 1	Phase 1	9/28/2004				
A-71378		Abbott Laboratories	Obesity		Phase 2	Discontinued	7/2/1993	7/2/1993			
A-75998		Abbott Laboratories	Estrogen deficiency		Phase 1	Discontinued	7/2/1993				
Abarelix PPI-149	Plenaxis	Speciality European Pharma Ltd	Prostate cancer Endometriosis	Prostate cancer	Approved	Approved	7/2/1996		1/15/1999	11/25/2003	US
ABT-510		Abbott Laboratories	Non-small-cell lung cancer Renal cell carcinoma Sarcoma Lymphoma Cancer Solid tumors Metastatic melanoma Malignant glioma		Phase 2	Phase 2	4/15/2000	1/15/2003			
AC-100	Dentonin	Acologix	Bone injury Tooth restoration		Phase 2	Phase 2	12/15/2002	5/15/2005			
AC-162352 PYY 3-36		Amylin Pharmaceuticals	Obesity		Phase 1	Phase I	7/2/2002				
AC-253	Antam	Amylin Pharmaceuticals	Obesity Type 2 diabetes		Phase 1	Discontinued	4/15/1994				
AC-2592	Betatropin	Amylin Pharmaceuticals	Heart failure		Phase 2	Discontinued	9/15/1999	7/2/2001			
AC-625		Amylin Pharmaceuticals	Hypertension Cardiovascular disease		Phase 1	Discontinued	1/15/1994	7/2/1994			
ACV-1		Metabolic Pharmaceuticals Ltd	Neuropathic pain Pain Wound healing		Phase 2	Discontinued	6/15/2005	6/15/2006			
ADH-1	Exherin	Adherex Technologies Inc	Solid tumors Malignant melanoma		Phase 2	Phase 2	12/15/2002	4/15/2005			
AEZS-108 AN-152 ZEN-008		AEterna Zentaris	Endometrial carcinoma Breast cancer Ovarian cancer Prostate cancer		Phase 2	Phase 2	1/15/2005	12/15/2007			

ALL PEPTIDES : ALPHABETICAL LISTING

INN and/ or Compound Name	Therapeutic Area Classification	Number of Amino acids	Topology	Coupled moiety	Manufacturing Method	Novelty	Action at Receptor	Molecular Target	Target Type	Target Location
A-6	Oncology	8	N/A	N/A	Synthetic		Anti-cancer	N/A	N/A	Extracellular (assumed)
A-623 623	AMG- Allergy & Immunology	N/A	N/A	N/A	Recombinant		Antagonist	B-cell activating factor	Cytokine	
A-71378	Metabolic	6	Linear	N/A	Synthetic	Follow-up	Agonist	CCK receptor	GPCR A	Extracellular
A-75998	Fertility	10	N/A	N/A	Synthetic	Follow-up	Antagonist	GnRH R	GPCR A	Extracellular
Abarelix 149	PPI- Oncology	10	Linear	N/A	Synthetic	Follow-up	Antagonist	GnRH R	GPCR A	Extracellular
ABT-510	Oncology	9	Linear	N/A	Synthetic	First-in-class	Agonist	CD36	Other receptor	Extracellular
AC-100	Dental	23	N/A	N/A	Synthetic	First-in-class	Agonist	PGE2 receptor	GPCR A	Extracellular
AC-162352 36	PYY 3- Metabolic	34	Linear	N/A	Synthetic	Follow-up	Agonist	NPY receptor	GPCR A	Extracellular
AC-253	Metabolic	N/A	N/A	N/A	Synthetic	Follow-up	Antagonist	CALC receptor + RAMPs	GPCR B	Extracellular
AC-2592	Cardiovascular	30	N/A	N/A	Recombinant	Follow-up	Agonist	GLP-1 receptor	GPCR B	Extracellular
AC-625	Cardiovascular	N/A	N/A	N/A	Synthetic	First-in-class	Antagonist	CALC receptor + RAMPs	GPCR B	Extracellular
ACV-1	Pain	16	N/A	N/A	Synthetic	First-in-class	Antagonist	Nicotinic ACH receptor	Channel	Extracellular
ADH-1	Oncology	5	Cyclic	N/A	Synthetic	First-in-class	Antagonist	N-Cadherin	Cell adhesion molecule	Extracellular
AEZS-108 152	AN- ZEN-008 Oncology	10	Linear	N/A	Synthetic	Follow-up	Antagonist	GnRH R	GPCR A	Extracellular